adagrasib,Pembrolizumab
mirati,merck
['pembro', 'lcsm,(-blcsm)', 'lung', 'nsclc', 'alexander', 'sclc', 'adagrasib', 'thoracic', 'mirati']
there is a lot to consider in this first-line study of the #kras g12c inhibitor adagrasib plus pembrolizumab from #esmoimmuno22. some pleasant surprises in terms of safety. definitely encouraging but need to see a bit more to be sold on this strategy. #lcsm 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Host Official @IASLC Podcast #LCSM #HereWeGo #ITYSL